Prognostic Importance of Comorbidity in a Hospital-Based Cancer Registry

摘要: Context Patients with cancer often have other medical ailments, referred to as comorbidity. Comorbidity may impact treatment decision-making, prognosis, and quality of care assessment. Objective To assess whether comorbidity information can provide important prognostic in a hospital-based registry. Design, setting, participants An observational prospective cohort study using data collected by trained registrars. was obtained through record review the Adult Evaluation 27, validated chart-based instrument. A total 17,712 patients receiving between January 1, 1995, 31, 2001, for primary diagnosis new prostate, lung (nonsmall cell), breast, digestive system, gynecological, urinary or head neck were included. Main outcome measure Duration months overall survival. Results 19,268 included study; median duration follow-up 31 months. Of these patients, 1556 (8.0%) excluded due missing unknown data. Severity strongly influenced survival dose-dependent fashion independent stage. Compared without comorbidity, adjusted hazard ratio associated mild 1.21 (95% confidence interval [CI], 1.13-1.30), moderate 1.86 CI, 1.73-2.00), severe 2.56 2.35-2.81). Adjusted Kaplan-Meier curves revealed that at any point time more levels had worse (partial chi2(3) 523.54; P Conclusions is an factor cancer. The inclusion registries will increase value use research.